See what happened at SABCS 2023  Learn more

2023 San Antonio
Breast Cancer Symposium®

December 5-9, 2023

Presentations of Interest

Click on abstract number to see the poster presented at SABCS 2023.

Oncotype DX Data

Update of RSClin® with extended TAILORx follow-up and development and validation of a new tool for risk of late distant recurrence
PO1-02-02 | Sparano

Concordance analysis of paired breast cancer core needle biopsies and surgical excision samples using the Oncotype DX Breast Recurrence Score® assay
PO4-08-09 | Nassar

Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of E4112
GS03-01 | Khan

Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTcycle trial (n=4,334).
LBO1-05  | Gluz

OncoExTra Data

Comparison of whole exome, whole transcriptome genomic profiling and targeted sequencing with 50-gene panels
PO5-13-05 | Thakkar

Classifying HER2-low breast cancer using a combination of ERBB2 mRNA expression and altered genes
PO5-13-06 | Basu

Prevalence of genomic alterations in Xerna tumor microenvironment subtypes in triple negative breast cancer patients
PO5-13-10 | Basu

PreventionGenetics Data

Cox: Hereditary cancer genetic testing in Puerto Rican females
PO1-08-08 | Cox


Insights for treatment decision making with the Oncotype DX Breast Recurrence Score® test and the RSClin® Tool

Learning Objectives

  • Recognize and discuss the increased prognostic information that may be offered to patients and clinicians by integrating the Oncotype DX Breast Recurrence Score® test with clinicopathologic characteristics
  • Describe the development and validation of the RSClin Tool for prognosis and prediction of chemotherapy benefit in patients with node-negative early-stage breast cancer
  • Analyze new updates to the RSClin Tool and interpret their effect on information offered by the tool
  • Introduce the RSClin Tool enhancement for late recurrence beyond 5 years and discuss its utility for patients and providers


Jennifer Racz MD

Director, Medical Affairs, Precision Oncology

Christy Russell MD - sabcs-2023

Vice President, US Medical Affairs, Precision Oncology

Jay Anderson MD

Co-Director, Compass Breast Specialists, Associate Chair, US Oncology Breast Cancer Research Committee

December 5-9, 2023